Celcuity heads into the final week of August with a notable split in its positioning signals — options traders are turning more bullish just as a large earnings-driven short is sitting still, and the Street's post-earnings tone is constructive but selective.
The most striking move this week is in options. The put/call ratio has dropped to 0.81, nearly two standard deviations below its 20-day mean of 0.95. That's the lowest reading on CELC in the past year, and it marks a sharp reversal from the previous two weeks when the ratio was hugging its annual high near 1.04. Calls are now clearly dominating the flow. The stock has added 11.7% over the past month to close at $92.27, and this week's 1.6% gain on Tuesday suggests the tape is cooperating with the more bullish options positioning.
Short interest tells a different story — one of persistent, elevated conviction from the bear camp. At roughly 21.8% of the free float, the short position is among the highest in US small-cap biotech. It ticked up 4.7% in a single session on August 25, though the one-week change is near flat at 0.07%, meaning Tuesday's move is more of a daily wobble than a fresh build. What's notable is the broader trend over the past six weeks: shorts have been gradually covering since early August, when the float-adjusted position ran above 23%. Despite that trimming, 21.8% is still a substantial overhang. The official FINRA data from the August 14 settlement confirms the same ballpark, at 10.5 million shares. Borrow conditions offer no urgency to either side — availability is comfortable at 196%, meaning roughly two shares are available for every one borrowed, and cost to borrow is just 0.57%, barely off recent lows. There is no squeeze pressure here; the shorts can hold.
The Street is bullish but trimming ambition after last week's earnings print. Gedatolisib's Q2 release landed with a muted market reaction — the stock fell just 0.09% the day after the August 13 announcement and drifted a further 1.6% over the following five days. That contrasts with the previous earnings event in mid-August 2026 which saw a 6.7% single-day gain. Analysts responded by maintaining Buy-equivalent ratings across the board, but several trimmed targets: Stifel cut to $150 from $175 and Needham lowered to $140 from $157, both on August 14, while Guggenheim moved the other way, raising to $175 from $165 on August 17. The consensus mean sits at $161, implying roughly 75% upside from the current price. The bull case centers on Revtorpyk's commercial shipment guidance for late Q3 2026 and the prospect of an sNDA submission for PIK3CA-mutant patients that quarter. Bears point to the FDA's documented concerns about adverse events, dose modifications, and a competitive HR+/HER2- breast cancer landscape. EPS momentum over the past 30 days ranks in the 97th percentile, suggesting estimate revisions are still running hard in the right direction.
Insider activity is worth flagging, though not as a fresh signal. Baker Bros Advisors, a long-standing biotech specialist and 5% owner, sold just over 3.1 million shares on July 14 at $102.50 — a combined $317 million exit at a price meaningfully above where the stock trades today. That exit, while six weeks old, coincides with a stock that has pulled back from those levels and gives context to the short interest: some of the recent float increase likely reflects that overhang finding a new clearing price.
The peer group drifted unevenly this week. HRTX gained 7.4% and CLNN added 8.6%, while PRAX slipped 0.5% and DNTH fell 3%. CELC's own 1% weekly decline sits roughly in the middle of that range, suggesting the tape is more about stock-specific positioning than sector rotation.
The next scheduled catalyst is the November 13 earnings event, but September's anticipated commercial shipment update for Revtorpyk — flagged explicitly by management as a potential stock catalyst — is the nearer-term event to watch.
See the live data behind this article on ORTEX.
Open CELC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
